Format

Send to

Choose Destination
Br J Cancer. 1996 Aug;74(4):648-9.

Phase I trial of elactocin.

Author information

1
Department of Medical Oncology, Charing Cross Hospital, London, UK.

Abstract

Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.

PMID:
8761384
PMCID:
PMC2074658
DOI:
10.1038/bjc.1996.415
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center